Can Shorter RT Offer Long-Term Benefits in Prostate Cancer?
METHODOLOGY:
The initial findings from the phase III randomized trial demonstrated superior cancer control with dose-escalated hypofractionated than with conventional intensity-modulated radiation therapy in patients with localized prostate cancer, at a median follow-up of 8.5 years.
In the latest analysis, the researchers assessed patient outcomes at a median follow-up of 13.2 years to determine whether the benefit offered by hypofractionation was maintained.
In the study, 206 patients with localized prostate cancer were randomly assigned to receive either hypofractionated (72 Gy in 2.4-Gy fractions over 6 weeks; n = 104) or conventional intensity-modulated radiation therapy (75.6 Gy in 1.8-Gy fractions over 8.4 weeks; n = 102).
Overall, 71% of patients had intermediate-risk prostate cancer, 48% had Gleason grade group 2 prostate cancer, 90% had a prostate-specific antigen (PSA) level of ≤ 10 ng/mL, and 24% received androgen-deprivation therapy.
The primary outcome was treatment failure, defined as PSA failure or the initiation of salvage therapy.
TAKEAWAY:
Fewer patients experienced treatment failure with hypofractionated radiotherapy (n = 13) than with conventional radiotherapy (n = 22), although the difference was no longer statistically significant ( P = .08). All patients in the hypofractionated group had PSA failure, whereas in the conventional group, 20 patients had PSA failure, and salvage therapy was initiated for two patients.
= .08). All patients in the hypofractionated group had PSA failure, whereas in the conventional group, 20 patients had PSA failure, and salvage therapy was initiated for two patients. Among patients who did not receive androgen-deprivation therapy, the 10-year failure rate was significantly lower with hypofractionated radiotherapy than with conventional radiotherapy (13% vs 26%; P = .04); this difference was not observed among those who received androgen-deprivation therapy.
= .04); this difference was not observed among those who received androgen-deprivation therapy. The 15-year overall survival favored hypofractionated radiotherapy (87% vs 75%) but did not reach statistical significance ( P = .08). The rate of distant metastases was not statistically different between the hypofractionated radiotherapy and conventional groups ( P = .2), and most events occurred beyond 9 years after starting radiotherapy.
= .08). The rate of distant metastases was not statistically different between the hypofractionated radiotherapy and conventional groups ( = .2), and most events occurred beyond 9 years after starting radiotherapy. Late grade ≥ 2 genitourinary toxicity at 10 years was not significantly different for the hypofractionated and conventional groups (26% vs 23%; P = .5), as was gastrointestinal toxicity (10% vs 4%; P = .09).
IN PRACTICE:
'Long-term outcomes show a reduction in treatment failure associated with dose-escalated, hypofractionated [radiotherapy] in patients with low-risk and intermediate risk prostate cancer not receiving [androgen-deprivation therapy ], with similar late genitourinary and gastrointestinal toxicities,' the authors wrote.
'In the years since initial publication, hypofractionated [intensity–modulated radiation therapy] has been adopted as the standard of care due to multiple randomized controlled trials and these long-term results supporting that [hypofractionated intensity–modulated radiation therapy] provides comparable outcomes to [conventionally fractionated intensity–modulated radiation therapy], with the added benefit of convenient treatment time for patients,' they concluded.
SOURCE:
This study, led by Comron Hassanzadeh, MD, MPH, The University of Texas MD Anderson Cancer Center in Houston, was published online in Journal of Clinical Oncology .
LIMITATIONS:
This study predominantly included patients with low-risk and intermediate-risk prostate cancer, and only some patients received androgen-deprivation therapy, and hence, the findings may not be generalizable to patients with high-risk disease. Additionally, toxicity results were applicable for patients receiving intensity–modulated radiation therapy with daily image guidance, although newer techniques could have further improved tolerability.
DISCLOSURES:
This study received support in part through a Cancer Center Support grant. Three authors reported being employees of the MD Anderson Cancer Center. Some authors declared receiving research funding or honoraria and having other ties with various sources.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Apple's blood oxygen monitoring returns to its latest Apple Watches
Apple announced on Thursday it's introducing a redesigned Blood Oxygen feature for some Watch Series 8, Series 10, and Apple Watch Ultra. With this move, Apple is bringing back blood oxygen monitoring by tweaking the feature to get around the International Trade Commission's (ITC) import ban. Blood oxygen data will be measured and calculated on the user's paired iPhone, and results can be viewed in the Respiratory section of the Health app. This means users won't be able to view the data on their Apple Watch, as they'll need to do so on their iPhone. Apple says the update announced today is enabled by a recent U.S. Customs ruling, which means that the tech giant is allowed to import Apple Watches with the redesigned Blood Oxygen feature. The change doesn't affect previously sold models with the original version of the feature or units bought outside the U.S. The redesigned feature only applies to Apple Watches that were sold after the ITC import ban took effect in early 2024. These users can access the redesigned Blood Oxygen feature through an iPhone and Apple Watch software update coming on Thursday. The move comes as Apple has been in an ongoing legal dispute with medical device maker Masimo, which has accused the tech giant of stealing its pulse oximetry technology after initial talks about a potential collaboration. In 2023, Masimo secured a victory against Apple at the ITC to block imports of Apple Watches with blood oxygen monitoring, after the commission found that Apple's technology infringed upon Masimo's patents. Apple then had to remove the feature. Apple counter-sued Masimo, claiming that the company copied Apple Watch features to use in its own smartwatches. The tech giant has also filed an appeal of the ITC ban. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Digital Trends
9 minutes ago
- Digital Trends
Blood oxygen measurement returns to the Apple Watch, sort of
Apple has just announced a software update that will enable the missing blood oxygen level measurement capability on the Apple Watch. The update will enable the biosensing feature on the Watch Series 9, Series 10, and the Apple Watch Ultra 2, once users update their iPhone and smartwatch to the latest build. What does it mean for users? In order to use the blood oxygen feature again on the Apple Watch Series 9, 10, and the Ultra 2, users will have to update their smartwatch to watchOS 11.6.1. The update is now rolling out to users in the United States. In addition to it, the feature will only work when users also update their iPhone to iOS 18.6.1, which has also been released simultaneously. Recommended Videos There's a crucial difference this time around. Instead of seeing the blood oxygen measurement on the Apple Watch screen, users will now have to open the Health app on their iPhone. That's because Apple is now doing the computation on the iPhone, instead of accomplishing it on the wearable and showing the results natively on the Apple Watch due to the patent dispute over alleged theft of the underlying pulse oximetry tech. 'Sensor data from the Blood Oxygen app on Apple Watch will be measured and calculated on the paired iPhone, and results can be viewed in the Respiratory section of the Health app,' instructs Apple. For all other Apple Watch models not affected by the patent dispute, they will continue to measure and show the measurements in the Blood Oxygen app on the smartwatch's screen. Why the hassle? So far, Apple Watch users have been able to track their blood oxygen saturation levels on their Apple Watch and see the readings on their wrists. But owing to a patent dispute with a company named Masimo and an import ban on models that offer this feature, the Cupertino-based company had to pull this capability after lengthy legal battles and an import ban handed down by the International Trade Commission The ban came into effect back in December of 2023, and despite a brief respite, Apple had to disable the blood oxygen features on the watches it sold following the trade restriction in the US. Apple has expressed disagreement with the charges leveled against it by Masimo, after the company filed two seprate lawsuits against the Apple Watch maker. Interestingly, Apple began working on a software-based workaround soon after the ITC ruling. It appears that the company was ready with an alternative route, but it's surprising that Apple took over a year and a half to enable it.
Forbes
10 minutes ago
- Forbes
AI And The Future Of Work: Andrew Yang's Caution Vs. Labor's Optimism
Andrew Yang, technology policy advocate and former presidential candidate, has been sounding alarms about automation's impact for years. At the Ai4 conference in Las Vegas, he was interviewed by Nancy Scola on his views of AI and universal basic income, while at another session, Taylor Stockton, Chief Innovation Officer at the U.S. Department of Labor shared the administration's plans to deal with AI and workforce disruption. The two offered sharply different takes on how artificial intelligence is reshaping the workforce, and what should be done about it. While Yang urges caution on AI-accelerated job disruption, Stockton says those predictions are missing the bigger story. Both see AI reshaping the labor market. They just disagree on what's needed to support the changing labor market. Yang: The Displacement Is Already Happening Yang doesn't speak in hypotheticals. He says CEOs have told him directly they've frozen hiring and started layoffs because AI tools are now doing work once assigned to humans. That shift isn't theoretical. It's already showing up in revised job numbers. From May to July, the bulk of new jobs came from healthcare, an industry still difficult to automate. Other sectors are seeing a slow drain. In his words, a 'tidal wave' is rolling through the economy while Washington stands 'inert or unresponsive.' He expects millions in call centers, retail, and food service to be hit, along with white-collar professionals who assumed they were safe. 'Anyone who thinks that the white-collar blood bath is nonsense is going to be wrong,' he said, warning it may only take months for skeptics to see the scale. The human cost, Yang added, doesn't always make headlines. 'If you're a 50-year-old executive who has lost a job, that's not a really sympathetic narrative to the population at large,' he noted. 'But that's a real impact for the family, and then you multiply that times 100,000 and we have a real problem.' His solution is to share the gains. If AI drives GDP per capita from $82,000 into six figures, part of that should reach households directly. He points to universal basic income and expanded child tax credits as ways to keep people afloat during upheaval. For Yang, it's not just about paychecks. Once the link between effort and reward breaks, he says, people stop trying. Younger generations, he warns, are already showing drops in conscientiousness and agreeableness. Some of that, he fears, can't be reversed. US Department of Labor: AI as an Engine for Opportunity Stockton's starting point is different. He doesn't buy into visions of empty offices and shuttered plants. 'The fear of mass job displacement is deeply overstated,' he says. History shows that major technology shifts, from mechanized farming to the Internet, ended with more jobs, not fewer. AI, in his telling, is following a similar pattern. He points to roles emerging right now such as AI prompt engineers and governance analysts, many of which don't require a traditional degree. In healthcare, AI is producing clinical notes so physicians can spend more time with patients. On factory floors and construction sites, sensors catch hazards before they become accidents. The Department of Labor's plan hinges on agility, tracking AI's impact on jobs in real time, using that data to adjust policy, and running pilot programs for rapid retraining. Stockton wants apprenticeships to become a core path into careers, targeting one million active placements in critical fields such as advanced manufacturing and AI infrastructure. He also wants AI literacy baked into education from K-12 to adult retraining. Stockton shared an emphasis on apprenticeships and alternatives to the traditional 4-year college education as a path to relevance in the AI-powered economy. A study he cited showed 52 percent of the Class of 2023 unemployed or underemployed a year after graduation. 'The College for All movement has failed,' he told the audience. 'A bachelor's degree no longer guarantees access to professional employment. Apprenticeships offer a faster, debt-free alternative…and combine paid job experience with training that directly maps to employer needs.' The federal approach isn't just reactive. In July, the White House released the 'America's AI Action Plan,' a 90-point blueprint under three main headings: Accelerating AI Innovation, Building American AI Infrastructure, and Leading in International AI Diplomacy and Security. It calls for streamlining permits for data centers and chip plants, strengthening the electric grid, creating regulatory sandboxes, and exporting a full-stack AI package to allies, while keeping U.S. values embedded in the technology. Stockton sees the plan as a wind at the back of his workforce push. Common Ground, Clear Differences Both Yang and Stockton agree AI's advance is fast and the pace will unsettle certain jobs. They see healthcare and other people-focused work as relatively safe for now. Both stress that while AI can handle parts of a process, people must decide what the system should aim for. Where they diverge is in the first move. Yang wants immediate income support to keep families stable while the market finds its footing. Stockton believes the priority is rapid adaptation including AI literacy, nimble training programs, and routes into new careers. Yang points to struggling college grads and laid-off mid-career workers. Stockton thinks some of those losses are more about post-pandemic corrections or strategic shifts than about AI alone. Studies fuel both arguments. McKinsey pegs the annual global productivity boost from generative AI at up to $4.4 trillion. PwC reports that jobs exposed to AI have grown 38 percent in the U.S. since the tech's arrival, though roles with less exposure have grown faster. News stories document both companies replacing whole teams with AI systems and companies using AI to amplify human work. In high-risk industries, AI has improved safety and output, which mirrors Stockton's vision in action. In customer service or routine analysis, AI is consolidating headcount, exactly what Yang warns about. What's Likely Ahead Over the next five years, productivity gains are likely to show up before job growth does. Companies that adopt AI early will push output higher without adding staff. Jobs will keep blending human skills with AI tools, making Stockton's AI literacy agenda more pressing. And if wages lag profits for too long, political pressure for income-based solutions could build quickly. Both men see high stakes. Stockton imagines a workforce ready to keep pace. Yang doubts the system can pivot fast enough. A blended strategy including training and adaptation alongside income support could prove the safest bet. Whether it's adopted may depend on whether policymakers, business leaders, and educators can keep up with the technology's acceleration. AI isn't waiting. Neither can the people whose jobs it touches.
